In colon cancer, upregulation of IGF2BP1 suppresses the CD8+ T-cells mediated antitumor immunity through reducing the tumor cytotoxicity and enhancing the target PD-L1 mRNA stability. This evidence concerns the gene IGF2BP1 and malignant colon neoplasm.